Comparative Analysis of the Effects of Intravenous Administration of Placental Mesenchymal Stromal Cells and Neural Progenitor Cells Derived from Induced Pluripotent Cells on the Course of Acute Ischemic Stroke in Rats
- Autores: Gubskii I.1, Salikhova D.2, Galitsina E.2, Leonov G.2, Chekhonin V.1, Gubskii L.1, Kisevev S.2,3, Goldstein D.2, Yarygin K.4, Cherkashova E.1, Burunova V.4, Bukharova T.2, Namestnikova D.1
-
Afiliações:
- N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
- Research Center for Medical Genetics
- N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences
- V. N. Orekhovich Research Institute of Biomedical Chemistry
- Edição: Volume 166, Nº 4 (2019)
- Páginas: 558-566
- Seção: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/241183
- DOI: https://doi.org/10.1007/s10517-019-04392-5
- ID: 241183
Citar
Resumo
We compared the effects of placental mesenchymal stromal cells and neural progenitor cells derived from induced human pluripotent cells after their intravenous administration to rats in 24 h after transitory occlusion of the middle cerebral artery. The therapeutic effects were evaluated by the dynamics of animal survival, body weight, neurological deficit, and the volume of infarction focus in 7, 14, 30, and 60 days after surgery. Intravenous injection of neural progenitor cells produced a therapeutic effect on the course of experimental ischemic stroke by increasing animal survival in the most acute period and accelerating compensation of neurological deficit and body weight recovery. Neural progenitor cells were more effective than mesenchymal stromal cells from human placenta. The effectiveness of intravenous transplantation of neural progenitor cells in the model of occlusion of the middle cerebral artery is shown by us for the first time, although the therapeutic effect of their direct transplantation into the brain has already been described.
Sobre autores
I. Gubskii
N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Email: dadnam89@gmail.com
Rússia, Moscow
D. Salikhova
Research Center for Medical Genetics
Email: dadnam89@gmail.com
Rússia, Moscow
E. Galitsina
Research Center for Medical Genetics
Email: dadnam89@gmail.com
Rússia, Moscow
G. Leonov
Research Center for Medical Genetics
Email: dadnam89@gmail.com
Rússia, Moscow
V. Chekhonin
N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Email: dadnam89@gmail.com
Rússia, Moscow
L. Gubskii
N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Email: dadnam89@gmail.com
Rússia, Moscow
S. Kisevev
Research Center for Medical Genetics; N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences
Email: dadnam89@gmail.com
Rússia, Moscow; Moscow
D. Goldstein
Research Center for Medical Genetics
Email: dadnam89@gmail.com
Rússia, Moscow
K. Yarygin
V. N. Orekhovich Research Institute of Biomedical Chemistry
Email: dadnam89@gmail.com
Rússia, Moscow
E. Cherkashova
N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Email: dadnam89@gmail.com
Rússia, Moscow
V. Burunova
V. N. Orekhovich Research Institute of Biomedical Chemistry
Email: dadnam89@gmail.com
Rússia, Moscow
T. Bukharova
Research Center for Medical Genetics
Email: dadnam89@gmail.com
Rússia, Moscow
D. Namestnikova
N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Autor responsável pela correspondência
Email: dadnam89@gmail.com
Rússia, Moscow
![](/img/style/loading.gif)